Dzmitry Skazau/iStock via Getty Images Codexis ( NASDAQ: CDXS ) said it has finalized a sales agreement with Crosswalk Therapeutics for its gene therapy programs for Fabry and Pompe disease that were discontinued by partner Takeda ( TAK ) in April 2023. Under the agreement, Codexis will be eligible to receive development and commercial milestone payments, along with a low-to-mid-single digit percentage royalty based on net sales. The company didn’t disclose financial details in its announcement of the finalized agreement .
Codexis noted that Crosswalk is led by former members of Takeda’s rare disease unit. More on Codexis Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript Codexis, Inc.
2024 Q1 - Results - Earnings Call Presentation Codexis GAAP EPS of -$0.16 beats by $0.02, revenue of $17.
1M beats by $3.8M Codexis Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Codexis.
